Abstract Number: 1205 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Canakinumab In a Cryopyrin-Associated Periodic Syndrome Cohort.A Single Center Experience
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) comprises a group of rare, but severe, autoinflammatory diseases, characterized by urticaria, periodic fever, central nervous system inflammation, arthropathy, and…Abstract Number: 1206 • 2013 ACR/ARHP Annual Meeting
Canakinumab Treatment Regimens In CAPS Patients
Background/Purpose: Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1β and approved for the treatment of CAPS in many countries including Europe and the…Abstract Number: 1207 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Patients With AA Amyloidosis Secondary To Familial Mediterranean Fever: A Single Centre Experience
Background/Purpose: The most frequent underlying diseases responsible for AA amyloidosis worldwide are rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis, while familial Mediterranean fever (FMF)…Abstract Number: 1208 • 2013 ACR/ARHP Annual Meeting
Canakinumab In Patients With FMF
Background/Purpose: In a recent pilot study, it was reported that Canakinumab reduced the frequency of attacks in 9 patients with Familial Mediterranean Fever (FMF) resistant…Abstract Number: 1209 • 2013 ACR/ARHP Annual Meeting
Starting Time Of Inflammatory Attacks In Patients With Familial Mediterranean Fever
Background/Purpose: Familial Mediterranean fever (FMF), the most common form of the hereditary autoinflammatory diseases, is characterized by recurrent self-limiting attacks of fever and/or serositis accompanied…Abstract Number: 1210 • 2013 ACR/ARHP Annual Meeting
Epicardial Adipose Tissue and Atherosclerosis In Patients With Familial Mediterranean Fever
Background/Purpose : Familial Mediterranean Fever (FMF) is a chronic autosomal recessive hereditary disease characterized by episodic attacks of fever and inflammation of serosal and synovial…Abstract Number: 1211 • 2013 ACR/ARHP Annual Meeting
Adult Autoinflammatory Phenotypes Associated With Heterozygous MEFV Mutations: A Continuum of Familial Mediterranean Fever?
Background/Purpose: Familial Mediterranean fever (FMF) is traditionally regarded as an autosomal recessive disease characterized by periodic fever, serositis, erysipelas-like erythema and good response to colchicine. The…Abstract Number: 1212 • 2013 ACR/ARHP Annual Meeting
Are Different Disease Subtypes With Distinct Clinical Expression Present In Familial Mediterranean Fever: Results Of a Cluster Analysis
Background/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disorder characterized by self limited attacks of fever and serositis. The disease expression may be different in…Abstract Number: 1213 • 2013 ACR/ARHP Annual Meeting
Low-Penetrance NLRP3-Variants
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) presents as rare, autosomal dominant disease spectrum, due to mutations in the NLRP3-gene which lead to excessive interleukin-1 (IL-1) release.…Abstract Number: 1174 • 2013 ACR/ARHP Annual Meeting
Impact Of Bariatric Surgery On Serum Urate Targets in People With Morbid Obesity and Diabetes: A Prospective Longitudinal Study
Background/Purpose: Weight loss leads to reduced serum urate (SU) in people with obesity. However, the clinical relevance of such reductions in SU are unknown. This…Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…Abstract Number: 1176 • 2013 ACR/ARHP Annual Meeting
Pharmacokinetics and Pharmacodynamics Of Pegloticase In Patients With End-Stage Renal Failure Receiving Hemodialysis
Background/Purpose: Among the estimated 8.3 million adults in the US with gout, approximately 40% have coexistent chronic kidney disease (CKD).1,2 Further, the presence of gout…Abstract Number: 1177 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
Background/Purpose: Canakinumab (CAN), a selective, fully human, monoclonal anti-IL-1β antibody has demonstrated long-term benefits in gouty arthritis (GA) patients (pts) by targeting the inflammatory pathway…Abstract Number: 1178 • 2013 ACR/ARHP Annual Meeting
Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To-Severe Renal Impairment: A Randomized Controlled Trial
Background/Purpose: Up to 20% of patients with hyperuricemia (serum urate [sUA] >6.8 mg/dL) and gout have moderate-to-severe renal impairment. Higher sUA (>8.5 mg/dL) may increase the…Abstract Number: 1179 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
Background/Purpose: Gout patients are at increased cardiovascular (CV) risk. Since atherosclerosis is an inflammatory process, anti-inflammatory strategies to reduce CV risk are currently being investigated.…